Andrew M. Ziolkowski
Andy has a 25-year career devoted to venture capital investing and merchant banking across a broad range in industries. Among his successful investments, he includes DexCom, Biomimetic Pharmaceuticals, FutureHealth, Tessera, i-STAT, and The Liposome Company. Andy has been a frequent speaker and panelist at venture capital forums and international conferences such as BIO.
Prior to joining MidPoint, Andy was a Managing Director of SAE Ventures and Forest Street Capital LLC, where he spent fourteen years as an investor and advisor to early stage healthcare and technology companies. Previously, he was Director, Venture Capital at CS First Boston Merchant Bank. Andy began his venture capital career at Whitehead Associates, a family investment fund. He was also an electrical engineer and plasma physicist at the Grumman Aerospace Corporation and Princeton University Plasma Physics Laboratory.
Andy holds a Masters of Business Administration from The Wharton School of Business and Finance, and has a Bachelors of Science in Engineering from the University of Pennsylvania , where he was a Grumman Scholar. He also attended Princeton University ’s Plasma Physics Department and the University of Pennsylvania ’s Department of Energy Management and Power, where he did graduate work.
